BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23541650)

  • 1. C1 and N5 derivatives of cerpegin: synthesis of a new series based on structure-activity relationships to optimize their inhibitory effect on 20S proteasome.
    Hovhannisyan A; Pham TH; Bouvier D; Qin L; Melikyan G; Reboud-Ravaux M; Bouvier-Durand M
    Bioorg Med Chem Lett; 2013 May; 23(9):2696-703. PubMed ID: 23541650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New C(4)- and C(1)-derivatives of furo[3,4-c]pyridine-3-ones and related compounds: evidence for site-specific inhibition of the constitutive proteasome and its immunoisoform.
    Hovhannisyan A; Pham TH; Bouvier D; Piroyan A; Dufau L; Qin L; Cheng Y; Melikyan G; Reboud-Ravaux M; Bouvier-Durand M
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1571-80. PubMed ID: 24534487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new series of N5 derivatives of the 1,1,5-trimethyl furo[3,4-c]pyridine-3,4-dione (cerpegin) selectively inhibits the post-acid activity of mammalian 20S proteasomes.
    Pham TH; Hovhannisyan A; Bouvier D; Tian L; Reboud-Ravaux M; Melikyan G; Bouvier-Durand M
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3822-7. PubMed ID: 22560566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenoxypropanolamine derivatives as selective inhibitors of the 20S proteasome β1 and β5 subunits.
    Hovhannisyan AA; Pham TH; Bouvier D; Tan X; Touhar S; Mkryan GG; Dallakyan AM; El Amri C; Melikyan GS; Reboud-Ravaux M; Bouvier-Durand M
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5172-5178. PubMed ID: 29113763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Design, synthesis and biological assay of novel tripeptidic tetrazoles as inhibitors of 20S proteasome].
    Ma YH; Xu B; Cui JR; Yang ZJ; Zhang LR; Zhang LH
    Yao Xue Xue Bao; 2012 Apr; 47(4):472-8. PubMed ID: 22799029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
    ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Keto phenylamides as P1'-extended proteasome inhibitors.
    Voss C; Scholz C; Knorr S; Beck P; Stein ML; Zall A; Kuckelkorn U; Kloetzel PM; Groll M; Hamacher K; Schmidt B
    ChemMedChem; 2014 Nov; 9(11):2557-64. PubMed ID: 25087721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes.
    Ettari R; Cerchia C; Maiorana S; Guccione M; Novellino E; Bitto A; Grasso S; Lavecchia A; Zappalà M
    ChemMedChem; 2019 Apr; 14(8):842-852. PubMed ID: 30829448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisbenzimidazole derivatives as potent inhibitors of the trypsin-like sites of the immunoproteasome core particle.
    Koroleva ON; Pham TH; Bouvier D; Dufau L; Qin L; Reboud-Ravaux M; Ivanov AA; Zhuze AL; Gromova ES; Bouvier-Durand M
    Biochimie; 2015 Jan; 108():94-100. PubMed ID: 25446655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
    Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M
    J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
    Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
    Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
    Liu H; Wu J; Ge Y; Li A; Li J; Liu Z; Xu Y; Xu Q; Li Y
    Bioorg Med Chem; 2018 Mar; 26(5):1050-1061. PubMed ID: 29426629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors.
    Yang Y; Wang K; Wu B; Yang Y; Lai F; Chen X; Xiao Z
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127508. PubMed ID: 32853683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 20S proteasome as novel biological target for organochalcogenanes.
    Piovan L; Milani P; Silva MS; Moraes PG; Demasi M; Andrade LH
    Eur J Med Chem; 2014 Feb; 73():280-5. PubMed ID: 24463395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of peptidomimetic boronates as proteasome inhibitors.
    Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
    Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors.
    Maccari R; Ettari R; Adornato I; Naß A; Wolber G; Bitto A; Mannino F; Aliquò F; Bruno G; Nicolò F; Previti S; Grasso S; Zappalà M; Ottanà R
    Bioorg Med Chem Lett; 2018 Feb; 28(3):278-283. PubMed ID: 29292224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells.
    Archer CR; Groll M; Stein ML; Schellenberg B; Clerc J; Kaiser M; Kondratyuk TP; Pezzuto JM; Dudler R; Bachmann AS
    Biochemistry; 2012 Aug; 51(34):6880-8. PubMed ID: 22870914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor.
    Hasegawa M; Yasuda Y; Tanaka M; Nakata K; Umeda E; Wang Y; Watanabe C; Uetake S; Kunoh T; Shionyu M; Sasaki R; Shiina I; Mizukami T
    Eur J Med Chem; 2014 Jan; 71():290-305. PubMed ID: 24321833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
    Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
    Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids.
    Zhang J; Han M; Ma X; Xu L; Cao J; Zhou Y; Li J; Liu T; Hu Y
    Chem Biol Drug Des; 2014 Nov; 84(5):497-504. PubMed ID: 24751157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.